Compare LQDT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | ARVN |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.6M | 781.0M |
| IPO Year | 2006 | 2018 |
| Metric | LQDT | ARVN |
|---|---|---|
| Price | $30.87 | $12.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $40.00 | $18.14 |
| AVG Volume (30 Days) | 177.0K | ★ 846.9K |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.09 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $476,669,000.00 | $312,300,000.00 |
| Revenue This Year | N/A | $11.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.56 | ★ N/A |
| Revenue Growth | 31.20 | ★ 93.86 |
| 52 Week Low | $21.67 | $5.90 |
| 52 Week High | $39.72 | $20.63 |
| Indicator | LQDT | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 55.88 |
| Support Level | $29.11 | $11.01 |
| Resistance Level | $32.18 | $12.74 |
| Average True Range (ATR) | 0.83 | 0.53 |
| MACD | -0.30 | -0.07 |
| Stochastic Oscillator | 56.68 | 78.10 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.